Key result
Elevated reticulated platelets linked to ~167% higher MACCE risk.
Why the study?
Do elevated reticulated platelets predict major adverse cardiovascular and cerebrovascular events in patients with coronary artery disease?
Meta-Analysis (n=2,213)
Do elevated reticulated platelets predict major adverse cardiovascular and cerebrovascular events in patients with coronary artery disease?
Odds Ratio: 2.67 (95% CI 1.87–3.81)
Elevated reticulated platelets are significantly associated with an increased risk of MACCE and cardiovascular death in patients with coronary artery disease.
Authors
No takes yet. Share an insight, caveat, or question.
May aid MACCE risk stratification in CAD; supports biomarker research but leaves open whether targeting improves outcomes.
Chiarito et al. (2023) conducted a meta-analysis in Coronary artery disease (n=2,213). Elevated reticulated platelets (RPshigh) vs. Patients without elevated reticulated platelets (RPslow) was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCE) (OR 2.67, 95% CI 1.87-3.81). Elevated reticulated platelets were significantly associated with a higher risk of major adverse cardiovascular and cerebrovascular events compared to non-elevated levels (OR 2.67; 95% CI 1.87-3.81).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: